Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the price target of $12.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Okunewitch has given his Buy rating due to a combination of factors that highlight Radiopharm Theranostics Limited’s promising pipeline and strategic advancements. The company is making significant progress with its lead internal Lu177 nanobody programs, RAD204 and RAD202, which have shown promising results in imaging studies and are approaching crucial data readouts in the second half of 2025. These programs have demonstrated effective tumor localization, which is considered a surrogate for efficacy, and have the potential for an abscopal immune effect, indicating a dual mechanism of action.
Additionally, Radiopharm Theranostics is advancing its F18 diagnostic program, RAD101, which has received Fast Track Designation and is expected to provide interim data soon. The company’s financial position is strong, with sufficient cash reserves to fund operations through these key milestones, potentially allowing for capital raising at a more favorable valuation if the upcoming data readouts are positive. This strategic positioning and the potential for significant clinical advancements underpin Okunewitch’s optimistic outlook and Buy rating for the stock.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.
RADX’s price has also changed slightly for the past six months – from $4.760 to $4.809, which is a 1.03% increase.